Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ATAC-seq profiling of lineage-traced exhausted and memory-like CD8+ T cell subsets during tumor progression

ABSTRACT: To investigate the epigenetic landscape of tumor-reactive exhausted CD8+ T cells, ATAC-seq was performed on fluorescence-activated cell sorted CD8+ T cell subsets isolated from Lag3^iCreERT2^ Rosa26^LSL-tdTomato^ mice bearing B16-F10 melanoma tumors. Chromatin accessibility profiles were generated for lineage-traced LAG3^+tdTomato^+, LAG3^-tdTomato^+, and corresponding control CD8+ T cell populations isolated from tumors and draining lymphoid tissues. These data were used to characterize chromatin accessibility changes associated with exhausted, progenitor-like, and memory-like CD8+ T cell states and to define epigenetic relationships among lineage-traced T cell populations.

ORGANISM(S): Mus musculus

PROVIDER: GSE337898 | GEO | 2026/07/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Tumor-specific memory-like progenitor exhausted CD8+ T cell subsets diverge into terminally exhausted cells and long-lived memory T cells

Project description:Chronic antigen stimulation induces CD8+ T cell exhaustion (TEX) in tumors. To investigate the developmental fate and heterogeneity of exhausted T cells, we generated an inducible Lag3^iCreERT2 Rosa26^LSL-tdTomato lineage-tracing mouse model and profiled lineage-traced CD8+ T cells isolated from tumors and peripheral lymphoid tissues at multiple time points following B16-F10 melanoma challenge. Single-cell RNA sequencing, paired TCR sequencing, and ATAC-seq were performed to characterize transcriptional, clonal, and epigenetic states of LAG3^+tdTomato^+, LAG3^-tdTomato^+, and corresponding control CD8+ T cell populations. These datasets provide a resource for studying the differentiation trajectories, clonal relationships, and chromatin remodeling underlying exhausted and memory-like tumor-reactive CD8+ T cells.

2026-07-24 | GSE337902 | GEO

Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T cell exhaustion and reinvigorates antitumor immunity

Project description:LAG3 is a critical inhibitory receptor that is highly enriched on exhausted T cells within the tumor microenvironment (TME), where it functions as a key driver of T cell exhaustion-an archetypal barrier to robust antitumor immunity. In a colon cancer model, we identified that LAG3+CD8+ tumor-infiltrating lymphocytes (TILs) constitute the predominant tumor-specific T cells but exhibit defective IL2 signaling. To address whether exogenous IL2 replenishment unpins their dysfunction, we engineered LAG3-LaIL2 (low-affinity IL2), a fusion protein delivering IL2 selectively to LAG3+CD8+ TILs. LAG3-LaIL2 expanded pre-exhausted tumor-specific CD8+ T cells, reprogrammed their exhaustion trajectory toward an intermediate effector state, and prevented terminal exhaustion, leading to tumor regression and prolonged survival in mice. Mechanistically, LAG3-LaIL2 restored IL2R-JAK3-STAT5 signaling by upregulating the high-affinity IL2 receptor subunit CD122, thereby rejuvenating TIL functionality. Furthermore, LAG3-LaIL2 amplified tumor-specific effector and memory T cells in draining lymph nodes, enabling systemic antitumor immunity against distal tumors and preventing tumor recurrence. Collectively, our findings validate LAG3-LaIL2 as a precision immunotherapeutic agent that specifically targets exhausted TILs, concomitantly enhancing therapeutic efficacy and safety by restricting IL2 exposure to non-target cells. This strategy provides a translatable approach to overcoming T cell exhaustion in solid tumors, offering a promising avenue to improve clinical outcomes for cancer patients

2026-02-28 | GSE318979 | GEO

Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3

Project description:CD8+ T cell exhaustion is a distinct differentation state resulting from chronic antigen exposure and leading to hierarchical loss of effector functions. Using a murine model of diabetes, we show that CD8+ T cells derived from the islets of diabetic mice have CD8+ T cells that are canonically exhausted and yet retain sufficient effector function to contribute to pathogenicity in autoimmune diabetes. Genetic deletion of the inhibitory receptor LAG3 restricted to only CD8+ T cells lead to accelerated disease, with LAG3 deficient CD8+ T cells having enhanced effector function and trafficking. These findings reveal a distinct role of LAG3 in restraining autoreactive CD8+ T cells and implicate LAG3 as a potential therapeutic target in autoimmunity.

2022-04-08 | GSE199357 | GEO

ATAC-seq profiling of lineage-traced exhausted and memory-like CD8+ T cell subsets during tumor progression

Project description:ATAC-seq profiling of lineage-traced exhausted and memory-like CD8+ T cell subsets during tumor progression

| PRJNA1491467 | ENA

Single-cell transcriptome and TCR repertoire of PD-1 fate-mapped immune cells during cyclophosphamide and PD-1 blockade in syngeneic subcutaneous LLC tumor allografts

Project description:Processed single-cell datasets from Pdcd1-CreERT2 × Rosa26-tdTomato fate-mapping mice bearing subcutaneous LLC allografts and treated with CTX, anti-PD-1, or both. We provide count matrices, cell-level annotations, and per-cell TCR clonotypes; raw reads for transcriptome, sample-tag, and TCR libraries are deposited under ENA BioProject PRJEB100721. This resource profiles PD-1 lineage cells, highlighting therapy-dependent changes in progenitor-exhausted CD8 T cells and TCR clonotype dynamics.

2026-03-11 | E-MTAB-15883 | biostudies-arrayexpress

Single-cell RNA sequencing of spinal cord CD133+ DNGR-1 traced and CD133+ non-traced cells

Project description:Using CD133 as a pan-ependymal cell marker, we wished to understand whether CD133+ DNGR-1 traced cells constituted a distinct subset of ependymal cells by comparing these at the single cell level with CD133+ non-traced cells purified from spinal cords of DNGR-1 lineage tracer mice.

2022-06-30 | GSE202959 | GEO

Chromatin accessibilty profiling of SCA1+ and SCA1- lineage traced VSMCs

Project description:VSMCs expressing SCA1 have increased proliferative capacity (Dobnikar et al, 2018; Worssam et al, 2022; Pan et al, 2020). We therefore, mapped chromatin accessibility changes using bulk ATAC-seq for SCA1+ and SCA1- lineage traced VSMCs.

2024-04-09 | GSE246646 | GEO

Post-Radiotherapy GSCs EGR1-Induced GAL3 Upregulation and T Cell Exhaustion in GBM

Project description:Background: Glioblastoma (GBM), a highly aggressive brain cancer, inevitably recurs due to therapy-resistant glioblastoma stem cells (GSCs). Lymphocyte activation gene 3 (LAG3) contributes to T cell exhaustion, a key immune escape mechanism. Here, we investigate that the more exhausted state of GBM-infiltrating T cells after recurrence is associated with the LAG3 and its ligand galectin 3 (GAL3). Methods: The analysis of Single-cell RNA sequencing to characterize the landscape of immune cells in newly diagnosed GBMs and recurrent GBMs respectively. Post-radiotherapy GAL3 in GSCs upregulation was validated via cell biology experiments. In vitro/in vivo loss-of-function assays assessed GAL3's impact on CD4+/CD8+ T cell cytotoxicity against GSCs. Chromatin immunoprecipitation quantitative real-time PCR was leveraged to map the regulation of GAL3 after radiotherapy in GSCs. Results: The phenomenon that recurrent glioma patients had their T cells in a more exhausted state compared to primary glioma patients, is associated with the expression of LAG3. Elevated EGR1 in post-radiotherapy GSCs upregulates LAG3 ligand GAL3 expression in GSCs, impairing CD4+/CD8+ T-cell cytotoxicity. Small molecule inhibitors targeting EGR1 in combination with anti-LAG3 monoclonal antibody suppressed GBM tumor growth and prolonged survival of orthotopic xenograft-bearing mice. Conclusions: GAL3 in GSCs plays critical roles in maintaining the exhaustion stage of T cells and inhibits cytotoxic capacity of CD4+/CD8+ T cells, highlighting an interplay between GSCs and GBM-infiltrating T cells. Small molecule inhibitors in combination with anti-LAG3 monoclonal antibody may effectively improve GBM treatment.

2025-04-20 | GSE294744 | GEO

Single-cell RNA sequencing of spinal cord CD133+ DNGR-1 traced and CD133+ non-traced cells

Project description:Single-cell RNA sequencing of spinal cord CD133+ DNGR-1 traced and CD133+ non-traced cells

| PRJNA837893 | ENA

Combined PD-L1/TGFb blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors

Project description:TGFb signaling is a major pathway associated with poor clinical outcome in patients with advanced metastatic cancers and non-response to immune checkpoint blockade, particularly in the immune-excluded tumor phenotype. While previous pre-clinical studies demonstrated that converting tumors from an excluded to an inflamed phenotype and curative anti-tumor immunity require attenuation of both PD-L1 and TGFb signaling, the underlying cellular mechanisms remain unclear. Recent studies suggest that stem cell-like CD8 T cells (TSCL) can differentiate into non-exhausted CD8 T effector cells that drive durable anti-tumor immunity. Here, we show that TGFb and PD-L1 restrain TSCL expansion as well as replacement of progenitor exhausted and dysfunctional CD8 T cells with non-exhausted IFNghi CD8 T effector cells in the tumor microenvironment (TME). Blockade of TGFb and PD-L1 generated IFNghi CD8 T effector cells with enhanced motility, enabling both their accumulation in the TME and increased interaction with other cell types. Ensuing IFNg signaling markedly transformed myeloid, stromal, and tumor niches to yield a broadly immune-supportive ecosystem. Blocking IFNg completely abolished the effect of anti-PD-L1/ TGFb combination therapy. Our data suggest that TGFb works in concert with PD-L1 to prevent TSCL expansion and replacement of exhausted CD8 T cells with fresh CD8 T effector cells, thereby maintaining the CD8 T cell compartment in a dysfunctional state.

2023-06-16 | MSV000092193 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data